Pharvaris (PHVS) Competitors $23.05 +1.07 (+4.87%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$23.10 +0.04 (+0.20%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHVS vs. ACAD, KRYS, CYTK, MENS, ADMA, PCVX, AAPG, PTCT, ACLX, and AKROShould you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), Cytokinetics (CYTK), Jyong Biotech (MENS), ADMA Biologics (ADMA), Vaxcyte (PCVX), Ascentage Pharma Group International (AAPG), PTC Therapeutics (PTCT), Arcellx (ACLX), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry. Pharvaris vs. Its Competitors ACADIA Pharmaceuticals Krystal Biotech Cytokinetics Jyong Biotech ADMA Biologics Vaxcyte Ascentage Pharma Group International PTC Therapeutics Arcellx Akero Therapeutics Pharvaris (NASDAQ:PHVS) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability. Which has more risk & volatility, PHVS or ACAD? Pharvaris has a beta of -2.8, meaning that its stock price is 380% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Does the media favor PHVS or ACAD? In the previous week, ACADIA Pharmaceuticals had 13 more articles in the media than Pharvaris. MarketBeat recorded 16 mentions for ACADIA Pharmaceuticals and 3 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.86 beat ACADIA Pharmaceuticals' score of 0.55 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 13 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in PHVS or ACAD? 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 11.8% of Pharvaris shares are held by insiders. Comparatively, 26.5% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is PHVS or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 21.80% compared to Pharvaris' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 14.69% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets PharvarisN/A -69.09% -63.34% ACADIA Pharmaceuticals 21.80%14.69%9.41% Do analysts recommend PHVS or ACAD? Pharvaris presently has a consensus price target of $34.00, suggesting a potential upside of 47.51%. ACADIA Pharmaceuticals has a consensus price target of $28.88, suggesting a potential upside of 14.31%. Given Pharvaris' stronger consensus rating and higher possible upside, analysts clearly believe Pharvaris is more favorable than ACADIA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharvaris 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80ACADIA Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.61 Which has preferable earnings and valuation, PHVS or ACAD? ACADIA Pharmaceuticals has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharvarisN/AN/A-$145.24M-$3.36-6.86ACADIA Pharmaceuticals$1.02B4.18$226.45M$1.3318.99 SummaryACADIA Pharmaceuticals beats Pharvaris on 13 of the 16 factors compared between the two stocks. Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHVS vs. The Competition Export to ExcelMetricPharvarisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.15B$3.12B$5.79B$9.92BDividend YieldN/A2.28%6.71%4.53%P/E Ratio-6.8621.1076.0826.13Price / SalesN/A229.57460.9379.98Price / CashN/A44.9736.9659.04Price / Book4.169.8711.486.09Net Income-$145.24M-$53.42M$3.29B$266.51M7 Day Performance6.47%2.93%1.27%0.45%1 Month Performance8.57%9.85%7.94%4.58%1 Year Performance20.55%15.74%62.93%26.04% Pharvaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHVSPharvaris2.9748 of 5 stars$23.05+4.9%$34.00+47.5%+20.7%$1.15BN/A-6.8630News CoverageHigh Trading VolumeACADACADIA Pharmaceuticals3.9605 of 5 stars$25.99-0.9%$28.88+11.1%+55.7%$4.38B$957.80M19.54510Analyst DowngradeKRYSKrystal Biotech4.9184 of 5 stars$147.70-2.0%$210.38+42.4%-19.2%$4.27B$290.52M30.02210Positive NewsCYTKCytokinetics4.0172 of 5 stars$35.33-5.4%$71.58+102.6%-5.2%$4.23B$18.47M-6.93250Trending NewsAnalyst ForecastInsider TradeOptions VolumeMENSJyong BiotechN/A$54.81-1.3%N/AN/A$4.17BN/A0.0031News CoverageGap DownADMAADMA Biologics3.757 of 5 stars$17.26-0.7%$27.67+60.3%+0.8%$4.12B$426.45M20.07530Positive NewsPCVXVaxcyte2.7128 of 5 stars$30.79+0.1%$136.50+343.3%-70.5%$4.00BN/A-7.49160News CoveragePositive NewsAAPGAscentage Pharma Group InternationalN/A$42.47+3.3%N/AN/A$3.95B$134.35M0.00600Positive NewsGap UpPTCTPTC Therapeutics4.0686 of 5 stars$49.33-0.9%$69.15+40.2%+81.2%$3.92B$806.78M7.081,410News CoverageAnalyst ForecastACLXArcellx2.6304 of 5 stars$69.39-1.2%$114.31+64.7%+3.2%$3.85B$107.94M-20.2980News CoveragePositive NewsAKROAkero Therapeutics4.0043 of 5 stars$46.73-0.4%$81.57+74.6%+69.7%$3.74BN/A-23.3730Trending NewsAnalyst ForecastInsider TradeAnalyst Revision Related Companies and Tools Related Companies ACADIA Pharmaceuticals Alternatives Krystal Biotech Alternatives Cytokinetics Alternatives Jyong Biotech Alternatives ADMA Biologics Alternatives Vaxcyte Alternatives Ascentage Pharma Group International Alternatives PTC Therapeutics Alternatives Arcellx Alternatives Akero Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHVS) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredScientists Discover Untapped Energy Source in Heart of USACrash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredOdd “310F trade” doubles investor’s money in just 3 days?Have you heard of 310F? This unusual trade setup has quietly delivered one of the most consistent profit st...Eagle Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHVS Stock Alerts